S
Stephan A. Grupp
Researcher at Children's Hospital of Philadelphia
Publications - 396
Citations - 44427
Stephan A. Grupp is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Transplantation. The author has an hindex of 77, co-authored 366 publications receiving 34450 citations. Previous affiliations of Stephan A. Grupp include University of Pennsylvania & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy
Nathan Singh,Noelle V. Frey,Boris Engels,David M. Barrett,Olga Shestova,Pranali Ravikumar,Amy Shyu,Steven L. Highfill,Linlin Zhao,Liaomin Peng,Brian Granda,Melissa Ramones,Xeuqing Maggie Lu,David A. Christian,Jessica Perazzelli,Simon F. Lacey,Nathan H. Roy,Janis K. Burkhardt,Florent Colomb,Mohamed Abdel-Mohsen,Regina M. Young,Jennifer Brogdon,Stephan A. Grupp,Carl H. June,Shannon L. Maude,Saar Gill,Marco Ruella +26 more
TL;DR: A novel, affinity-enhanced CD22 CAR is designed and it is confirmed that shorter linker length improves anti-tumor activity and impacts CAR biology and regulates CAR-driven T cell activity.
Journal ArticleDOI
A Phase I Trial of Sirolimus (Rapamycin) in Pediatric Patients with Relapsed/Refractory Leukemia.
Susan R. Rheingold,Nancy Sacks,Yueh J. Chang,Valerie I. Brown,David T. Teachey,Beverly J. Lange,Stephan A. Grupp +6 more
TL;DR: Sirolimus was well tolerated in pediatric patients due to its ease of administration and lack of toxicity, and evidence of inhibition of mTOR is shown, manifested by a decrease in phosphorylated S6, suggesting that S6 may be used as a biomarker for response to mTOR inhibition.
Journal ArticleDOI
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Karen Thudium Mueller,Stephan A. Grupp,Shannon L. Maude,John E. Levine,Michael A. Pulsipher,Michael Boyer,Keith J. August,G. Doug Myers,Constantine S. Tam,Ulrich Jaeger,Stephen Ronan Foley,Peter Borchmann,Stephen J. Schuster,Edmund K. Waller,Rakesh Awasthi,Bernd Potthoff,Andy Warren,Edward Waldron,Fraser McBlane,Andrea Chassot-Agostinho,Theodore W. Laetsch +20 more
TL;DR: Tisagenlecleucel is indicated for pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and adults with r/r diffuse large b-cell lymphoma (DLBCL) as discussed by the authors.
Journal ArticleDOI
Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group.
Rudolph Kirk R. Schultz,K. S. Baker,Jaap Jan Boelens,Catherine M. Bollard,R. Maarten Egeler,M.J. Cowan,Ruth Ladenstein,Arjan C. Lankester,Franco Locatelli,Anita Lawitschka,John E. Levine,Mignon L. Loh,Eneida R. Nemecek,Charlotte M. Niemeyer,Vinod K. Prasad,Vanderson Rocha,Shalini Shenoy,Brigitte Strahm,Paul Veys,Donna A. Wall,Peter Bader,Stephan A. Grupp,Michael A. Pulsipher,Christina Peters +23 more
TL;DR: This meeting led to the creation of an international HCT network, dubbed the Westhafen Intercontinental Group, to develop worldwide priorities and strategies to address pediatric HCT issues.
Journal ArticleDOI
Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells
Marco Ruella,David M. Barrett,Saad S. Kenderian,Olga Shestova,Ted J. Hofmann,John Scholler,Simon F. Lacey,J. Joseph Melenhorst,Farzana Nazimuddin,Jessica Perazzelli,David A. Christian,Christopher A. Hunter,David L. Porter,Carl H. June,Stephan A. Grupp,Saar Gill +15 more
TL;DR: The goal of this study was to pre-clinically evaluate the impact of targeting both CD19 and CD123 with chimeric antigen receptor T cells for the treatment and prevention of CD19-negative relapses occurring after CD19/CD3-directed therapies.